等待开盘 10-21 09:30:00 美东时间
0.000
0.00%
Monopar Therapeutics Inc. announced that its Phase 2 ALXN1840-WD-204 copper balance study abstract has been selected for oral presentation at the AASLD Liver Meeting 2025. The session, titled "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline," will take place on November 9, 2025, at 9:00-9:15 am EST. For more details, visit the conference website or www.monopartx.com.
10-15 12:00
Monopar Therapeutics Inc. announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at $67.67 per share, with pre-funded warrants offered to certain investors. The gross proceeds are expected to be approximately $100 million, with $35 million allocated to purchasing shares from Tactic Pharma, LLC. The company plans to use the remaining net proceeds for general corporate purposes, including research and d...
09-24 03:08